Quick Dispatch:
Your glp-1-directed nmda receptor antagonism for obesity treatment Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your glp-1-directed nmda receptor antagonism for obesity treatment Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies ships.
Need Help?
Questions about glp-1-directed nmda receptor antagonism for obesity treatment Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for glp-1-directed nmda receptor antagonism for obesity treatment Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies in your area.
Nature: Dual-active molecules targeting GLP-1R and NMDA receptors exhibit superior anti-obesity effects
22.88
GLP-1 Receptor Agonists and Research to Treat Overeating and Substance Use Disorders
28.59
Targeting Obesity: GLP-1R, GIPR, GDF8 as Key Therapeutic Agents
26.30
Neurobiological Mechanisms and Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Binge Eating Disorder: A Narrative Review
26.54
Metabolic Flux Adaptations During GLP-1 Receptor Agonist Therapy: Redox Implications | Current Obesity Reports
24.98
Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies
22.29
Frontiers
29.05
